Loading...

APC anti-mouse CD3 Antibody

Pricing & Availability
Clone
17A2 (See other available formats)
Regulatory Status
RUO
Other Names
T cell antigen receptor complex, T3
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
17A2_APC_073012
C57BL/6 mouse splenocytes were stained with CD3 (clone 17A2) APC (filled histogram) or rat IgG2b, κ isotype control (open histogram).
  • 17A2_APC_073012
    C57BL/6 mouse splenocytes were stained with CD3 (clone 17A2) APC (filled histogram) or rat IgG2b, κ isotype control (open histogram).
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
100235 25 µg 33 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100236 100 µg 77 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD3, also known as T3, is a member of the Ig superfamily and primarily expressed on T cells, NK-T cells, and at different levels on thymocytes during T cell differentiation. CD3 is composed of CD3ε, δ, γ and ζ chains. It forms a TCR complex by associating with TCR α/β or γ/δ chains. CD3 plays a critical role in TCR signal transduction, T cell activation, and antigen recognition by binding the peptide/MHC antigen complex

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
γδTCR-positive T-T hybridoma D1
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Additional reported application (for relevant formats) include: spatial biology (IBEX)1,2.

Application References

(PubMed link indicates BioLegend citation)
  1. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  2. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Rivas MA, et al. 2021. Nat Immunol. 22:240. PubMed
  2. Xiang G, et al. 2022. Cell Death Dis. 13:451. PubMed
  3. Pani F, et al. 2021. Endocrinology. 162:. PubMed
  4. Hilfenhaus G, et al. 2021. Cancer Res. 81:619. PubMed
  5. Denny L, et al. 2021. Clin Transl Immunology. 10:e1234. PubMed
  6. Ramos SA, et al. 2022. J Allergy Clin Immunol. 149:767. PubMed
  7. Zhou Y, et al. 2021. Methods Mol Biol. 2388:35. PubMed
  8. Sugiura A, et al. 2022. Immunity. 55:65. PubMed
  9. Alam A, et al. 2022. Cancer Cell. 40:153. PubMed
  10. Cautivo KM, et al. 2022. Immunity. 55:254. PubMed
  11. Qi X, et al. 2022. FASEB J. 36:e22250. PubMed
  12. van Dierendonck XAMH, et al. 2022. Proc Natl Acad Sci U S A. 119:e2114739119. PubMed
  13. Corral D, et al. 2022. Cell Rep. 39:110715. PubMed
  14. Tu J, et al. 2022. Cancer Sci. 113:2496. PubMed
  15. Dolfi B, et al. 2022. Cell Rep. 39:110949. PubMed
  16. Du M, et al. 2022. Cancer Sci. 113:2974. PubMed
  17. Tessaro FHG, et al. 2022. Cell Rep. 39:110977. PubMed
  18. Grégoire C, et al. 2022. Immunity. 55:1216. PubMed
  19. Zhu J, et al. 2022. Research (Wash D C). 2022:9816272. PubMed
  20. Zhang Z, et al. 2022. Integr Cancer Ther. 21:15347354221138534. PubMed
  21. Miró L, et al. 2022. Cancers (Basel). 14: . PubMed
  22. An HW, et al. 2022. Cell Rep. 41:111878. PubMed
  23. Jin SM, et al. 2023. Nat Nanotechnol. :. PubMed
  24. Lin J, et al. 2023. Nat Commun. 14:224. PubMed
  25. Kang J, et al. 2023. JCI Insight. 8: . PubMed
  26. Chen Y, et al. 2023. Stem Cells Int. 2023:7482546. PubMed
  27. Li X, et al. 2022. Cell. 185:1709. PubMed
  28. Hou X, et al. 2020. Cell Reports. 28(1):172-189.e7.. PubMed
  29. Liu J, et al. 2019. Immunity. 50:600. PubMed
  30. Bergmann CA, et al. 2022. Cells. 11:. PubMed
  31. Akhtar MN, et al. 2022. MBio. 13:e0330921. PubMed
  32. Balakrishnan PB, et al. 2022. Nano Res. 15:2300. PubMed
  33. Shi X, et al. 2022. Proc Natl Acad Sci U S A. 119:e2208506119. PubMed
  34. Ho HM, et al. 2022. Pharmaceutics. 14:. PubMed
  35. Sparbier CE, et al. 2023. Nat Cell Biol. 25:258. PubMed
  36. Pan Y, et al. 2023. Adv Sci (Weinh). 10:e2206792. PubMed
  37. Wang X, et al. 2023. J Immunother Cancer. 11:. PubMed
  38. Liu N, et al. 2023. Cell Death Dis. 14:170. PubMed
  39. Gupta T, et al. 2023. Front Immunol. 14:1044703. PubMed
  40. Mabire M, et al. 2023. Nat Commun. 14:1830. PubMed
  41. Fu S, et al. 2023. Nat Commun. 14:2248. PubMed
  42. Li T, et al. 2023. Nat Commun. 14:2498. PubMed
  43. Zhang Z, et al. 2023. Aging Dis. 14:966. PubMed
  44. Bhaskar A, et al. 2023. iScience. 26:106644. PubMed
  45. Changsheng H, et al. 2023. Sci Adv. 9:eade4186. PubMed
  46. Cansever D, et al. 2023. Nat Immunol. . PubMed
  47. Koyama M, et al. 2015. J Exp Med. 212: 1303 - 1321. PubMed
  48. Morse M, et al. 2016. Lupus. 25: 81 - 87. PubMed
  49. Calabrese DR, et al. 2020. J Clin Invest. . PubMed
  50. Gabriely G, et al. 2021. iScience. 24:103347. PubMed
  51. Delvecchio FR, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:1543. PubMed
  52. Kim D, et al. 2021. Nanomicro Lett. 13:31. PubMed
  53. Yang H, et al. 2019. Mol Metab. 23:24. PubMed
  54. Naito Y, et al. 2019. American Journal of Physiology-Renal Physiology. 318(1):F238-F247. PubMed
  55. Fu X, et al. 2020. J Immunol. 205:2066. PubMed
  56. Song J, et al. 2021. J Am Heart Assoc. 10:e017329. PubMed
  57. Baram T, et al. 2021. Cells. 10:. PubMed
  58. Luo R, et al. 2021. Theranostics. 11:117. PubMed
  59. Pessoa Rodrigues C, et al. 2021. Sci Adv. 7:. PubMed
  60. Zhang S, et al. 2022. Cell Death Dis. 13:844. PubMed
  61. Wilson RP, et al. 2019. PLoS Pathog. 15:e1007745. PubMed
  62. Yu VWC et al. 2016. Cell. 167(5):1310-1322 . PubMed
  63. Huang X, et al. 2019. Cancer Immunol Res. 1.388888889. PubMed
  64. Gupta SS, et al. 2019. Cell Rep. 29:1862. PubMed
  65. Sano T, et al. 2021. Cell Reports. 36:109608. PubMed
  66. Greenberg J, et al. 2022. JCI Insight. Online ahead of print. PubMed
  67. Kremenovic M, et al. 2022. J Immunother Cancer. 10:. PubMed
  68. Yamamoto R et al. 2018. Cell stem cell. 22(4):600-607 . PubMed
  69. Forte E, et al. 2020. J Cell Mol Med. . PubMed
  70. Haque M, et al. 2021. STAR Protoc. 2:100264. PubMed
  71. Gruber T, et al. 2020. JCI Insight. 5:00. PubMed
  72. Fujino T, et al. 2021. Nat Commun. 12:1826. PubMed
  73. Shi S, et al. 2020. Clin Cancer Res. 26:5990. PubMed
  74. Almutairi F, et al. 2021. Front Immunol. 12:772288. PubMed
  75. Swidergall M, et al. 2019. Cell Rep. 28:423. PubMed
  76. Tsuchiya N, et al. 2020. Cell Reports. 29(1):162-175.e9.. PubMed
  77. Peng Z, et al. 2021. STAR Protocols. 2(2):100595. PubMed
  78. Wang X, et al. 2021. Front Cell Dev Biol. 632805:9. PubMed
  79. Zhang X, et al. 2022. Pharmaceutics. 14:. PubMed
  80. Tang D, et al. 2020. Br J Haematol. 191:906. PubMed
  81. van Elsas MJ, et al. 2022. Int J Mol Sci. 23:. PubMed
  82. Francian A, et al. 2021. J Drug Target. 29:754. PubMed
  83. Antunes KH, et al. 2022. Front Immunol. 13:867022. PubMed
  84. Mastandrea I, et al. 2022. STAR Protoc. 3:101106. PubMed
  85. Wu G, et al. 2020. Br J Pharmacol. 177:5063. PubMed
  86. Zhang Z, et al. 2021. Oncoimmunology. 10:1912472. PubMed
  87. Yoshimi A, et al. 2019. Nature. 574:273. PubMed
  88. Thomas S, et al. 2019. J Immunother Cancer. 7:214. PubMed
  89. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  90. Magod P, et al. 2021. Cell Reports. 36(5):109480. PubMed
  91. Li X, et al. 2020. Mol Ther. 28:2430. PubMed
  92. Guo W, et al. 2022. J Immunother Cancer. 10:. PubMed
  93. Ren HZ, et al. 2022. J Clin Transl Hepatol. 10:1138. PubMed
  94. Parada-Kusz M, et al. 2018. Dis Model Mech. 11:. PubMed
  95. Zhang F, et al. 2019. Immunity. 50:738. PubMed
  96. Liu H, et al. 2020. Cancer Cell. 37(3):324-339. PubMed
  97. Wang W, et al. 2022. Aging Cell. 21:e13630. PubMed
  98. Utz B, et al. 2020. Sci Rep. 10:18733. PubMed
  99. Hiramoto T, et al. 2018. Mol Ther. 26:1255. PubMed
  100. Yu VWC, et al. 2017. Cell. 168:944. PubMed
  101. Wang GZ, et al. 2019. Nat Commun. 10:1125. PubMed
  102. Chen X et al. 2017. Cell stem cell. 21(6):747-760 . PubMed
  103. Utley A, et al. 2020. Cell Rep. 31:107815. PubMed
  104. Suryawanshi RK, et al. 2021. Nat Commun. 12:6020. PubMed
  105. Du Y, et al. 2022. Nat Commun. 13:231. PubMed
  106. Zhang W, et al. 2019. Oncol Lett. 17:815. PubMed
  107. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
  108. Hu Q, et al. 2018. Nat Biomed Eng. 0.660416667. PubMed
  109. Xie Z, et al. 2020. Light Sci Appl. 0.486805556. PubMed
  110. Court AC, et al. 2020. EMBO Rep. 21:e48052. PubMed
  111. Venturutti L, et al. 2020. Cell. 182(2):297-316.e27. PubMed
  112. Zhao X, et al. 2022. Nat Protoc. 17:2240. PubMed
  113. Zuo W, et al. 2022. Cell Death Discov. 8:257. PubMed
  114. Reinfeld BI, et al. 2021. Nature. 593:282. PubMed
  115. Chauveau A, et al. 2020. Immunity. 52:794. PubMed
  116. Haikala HM, et al. 2019. Nat Commun. 10:620. PubMed
  117. Huang Z, et al. 2021. Nat Commun. 12:145. PubMed
  118. Zhu Y, et al. 2021. EMBO J. 40:e105320. PubMed
  119. Wang Y, et al. 2021. Front Microbiol. 12:701566. PubMed
  120. Zheng D, et al. 2022. Acta Pharm Sin B. 12:2740. PubMed
  121. Tomala J, et al. 2020. Methods Mol Biol. 2111:101. PubMed
  122. Wen M, et al. 2022. JCI Insight. Online ahead of print. PubMed
  123. Stirling ER, et al. 2022. J Immunother Cancer. 10:. PubMed
  124. Liu Y, et al. 2017. Oncogene. 10.1038/onc.2017.209. PubMed
  125. Hu J, et al. 2019. Mol Ther Nucleic Acids. 16:650. PubMed
  126. Burr ML, et al. 2019. Cancer Cell. 36:385. PubMed
  127. Liang J, et al. 2020. Sci Adv. 6:eabc3646. PubMed
  128. Kruta M, et al. 2021. Cell Stem Cell. :. PubMed
  129. Xiong W, et al. 2022. Adv Sci (Weinh). 9:e2103029. PubMed
  130. Xiao L, et al. 2021. Clin Cancer Res. 27:4338. PubMed
  131. Huang L, et al. 2021. Breast Cancer Res Treat. Online ahead of print. PubMed
  132. Han F, et al. 2020. Invest Ophthalmol Vis Sci. 61:24. PubMed
  133. Tomay F, et al. 2019. J Transl Med. 17:237. PubMed
  134. Li H, et al. 2021. Adv Sci (Weinh). 2001596:8. PubMed
  135. Yu H, et al. 2021. Front Oncol. 11:736882. PubMed
  136. Chen C, et al. 2021. J Virol. 95:e0082921. PubMed
  137. Martinez-Turtos A, et al. 2022. Oncoimmunology. 11:2116844. PubMed
  138. Zeng Q, et al. 2022. iScience. 25:105151. PubMed
  139. Xi‐Zhi J Guo et al. 2018. Immunity. 49(3):531-544 . PubMed
  140. Subramanian K, et al. 2019. Nat Microbiol. 4:62. PubMed
  141. Wang X, et al. 2020. Nat Commun. 4.505555556. PubMed
  142. Johnson DC, et al. 2020. Cell Death Dis. 0.894444444. PubMed
  143. Evgin L, et al. 2020. Nat Commun. 2.671527778. PubMed
  144. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  145. Xu P, et al. 2020. Cancer Immunol Res. 8:1193. PubMed
  146. Pascual-Pasto G, et al. 2022. J Immunother Cancer. 10:. PubMed
  147. Li Z, et al. 2022. Nat Commun. 13:6321. PubMed
  148. Olivo Pimentel V, et al. 2021. J Immunother Cancer. 9:. PubMed
  149. Li M, et al. 2021. Cancers (Basel). 13:. PubMed
  150. Cianciaruso C, et al. 2020. Cell Reports. 27(10):3062-3080.e11.. PubMed
  151. Zhang J, et al. 2018. Nature. 553:91. PubMed
  152. Adnan-Awad S, et al. 2020. Leukemia. . PubMed
  153. Liu Y, et al. 2020. Oncol Lett. 2369:20. PubMed
  154. Chen R, et al. 2021. Cell Reports. 34(7):108751. PubMed
  155. Nechama M, et al. 2018. Nat Commun. 9:1603. PubMed
  156. Liu YG, et al. 2019. FASEB J. 33:5018. PubMed
  157. Siddique SM, et al. 2019. Sci Rep. 9:13977. PubMed
  158. Jiang L, et al. 2020. Cell. 183(5):1219-1233.e18. PubMed
  159. Yu M, et al. 2021. Molecular Cell. 81(6):1216-1230.e9. PubMed
  160. Liu P, et al. 2020. Mol Cell. 748:77. PubMed
  161. Olson CA, et al. 2021. Cell Host Microbe. 29:1378. PubMed
  162. Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
  163. Kim S, et al. 2020. Autophagy. :1. PubMed
  164. Lazarian G, et al. 2021. Cancer Cell. 39(3):380-393.e8. PubMed
  165. Yoshida S, et al. 2022. PLoS One. 17:e0264317. PubMed
  166. Zhong C, et al. 2021. J Virol. 95:e0092521. PubMed
  167. Kelley WJ, et al. 2022. JCI Insight. 7: . PubMed
  168. Li K, et al. 2020. Nat Commun. 4.844444444. PubMed
  169. Hering L, et al. 2020. Front Immunol. 1.747222222. PubMed
  170. Hao L, et al. 2021. Br J Pharmacol. 178:4726. PubMed
  171. Lau P, et al. 2022. Cell Mol Immunol. :. PubMed
  172. Arora S, et al. 2021. Med (N Y). 2:938. PubMed
  173. Li H, et al. 2022. iScience. 25:104481. PubMed
  174. Hidalgo San Jose L, et al. 2020. Cell Rep. 30:69. PubMed
  175. Wang Y, et al. 2021. Cell Reports. 36(6):109516. PubMed
  176. Kujur W, et al. 2020. PLoS Pathog. 16:e1009132. PubMed
  177. Wang X, et al. 2021. Sci Transl Med. 13:. PubMed
  178. Rappe JCF, et al. 2021. J Exp Med. 218:. PubMed
  179. Lee A, et al. 2022. Nat Commun. 13:549. PubMed
  180. Agelidis A, et al. 2017. Cell Rep. 10.1016/j.celrep.2017.06.041. PubMed
  181. Sartorius R, et al. 2018. Front Immunol. 1.413888889. PubMed
  182. Hong Y, et al. 2019. J Extracell Vesicles. 8:1670893. PubMed
  183. Lightman SM, et al. 2020. Cell Reports. 1.086805556. PubMed
  184. Gardenier J, et al. 2017. Nat Commun. 8:14345. PubMed
  185. Heyde A, et al. 2021. Cell. 184(5):1348-1361.e22. PubMed
  186. Zeng A, et al. 2020. Oncol Rep. . PubMed
  187. Das A, et al. 2020. J Bone Miner Res. 36:199. PubMed
  188. Song X, et al. 2022. Transl Oncol. 15:101306. PubMed
  189. Akhtar MN, et al. 2020. PLoS Pathog. 16:e1009136. PubMed
  190. Zhang J, et al. 2021. Stem Cell Res Ther. 12:579. PubMed
  191. Chang MH, et al. 2021. Cell Rep. 37:109902. PubMed
  192. Xie Z, et al. 2020. Light Sci Appl. 9:161. PubMed
  193. Lake CM, et al. 2021. Cell Death Dis. 12:400. PubMed
  194. Pessoa Rodrigues C, et al. 2020. Sci Adv. 6:eaaz4815. PubMed
  195. Tripathi D, et al. 2016. Nat Commun. 7:13896. PubMed
RRID
AB_2561455 (BioLegend Cat. No. 100235)
AB_2561456 (BioLegend Cat. No. 100236)

Antigen Details

Structure
Ig superfamily, CD3/TCR, 20 kD
Distribution

Thymocytes (differentiation dependent), mature T cells, NK-T cells

Function
Antigen recognition, TCR signal transduction, T cell activation
Ligand/Receptor
Peptide antigen/MHC-complex
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Davis MM. 1990. Annu. Rev. Biochem. 59:475.
3. Weiss A, et al. 1994. Cell 76:263.

Gene ID
12502 View all products for this Gene ID
UniProt
View information about CD3 on UniProt.org

Other Formats

View All CD3 Reagents Request Custom Conjugation
Description Clone Applications
FITC anti-mouse CD3 17A2 FC
PE anti-mouse CD3 17A2 FC
Purified anti-mouse CD3 17A2 FC,IHC-F,IP,ICC
Alexa Fluor® 647 anti-mouse CD3 17A2 FC,IHC-F,3D IHC,SB
Alexa Fluor® 488 anti-mouse CD3 17A2 FC,IHC-F,3D IHC
Pacific Blue™ anti-mouse CD3 17A2 FC
Alexa Fluor® 700 anti-mouse CD3 17A2 FC
PerCP/Cyanine5.5 anti-mouse CD3 17A2 FC
PE/Cyanine7 anti-mouse CD3 17A2 FC
APC/Cyanine7 anti-mouse CD3 17A2 FC
Brilliant Violet 421™ anti-mouse CD3 17A2 FC,ICC
Brilliant Violet 570™ anti-mouse CD3 17A2 FC
Brilliant Violet 650™ anti-mouse CD3 17A2 FC
Brilliant Violet 785™ anti-mouse CD3 17A2 FC
Brilliant Violet 510™ anti-mouse CD3 17A2 FC
APC anti-mouse CD3 17A2 FC
Ultra-LEAF™ Purified anti-mouse CD3 17A2 FC,IHC-F,IP,ICC
Brilliant Violet 605™ anti-mouse CD3 17A2 FC
Alexa Fluor® 594 anti-mouse CD3 17A2 IHC-F,FC,3D IHC,SB
Brilliant Violet 711™ anti-mouse CD3 17A2 FC
Biotin anti-mouse CD3 17A2 FC,IHC-F
PE/Dazzle™ 594 anti-mouse CD3 17A2 FC
APC/Fire™ 750 anti-mouse CD3 17A2 FC
Brilliant Violet 750™ anti-mouse CD3 17A2 FC
TotalSeq™-A0182 anti-mouse CD3 17A2 PG
TotalSeq™-B0182 anti-mouse CD3 17A2 PG
Spark Blue™ 550 anti-mouse CD3 17A2 FC
Spark NIR™ 685 anti-mouse CD3 17A2 FC
TotalSeq™-C0182 anti-mouse CD3 17A2 PG
APC/Fire™ 810 anti-mouse CD3 17A2 FC
PE/Fire™ 640 anti-mouse CD3 17A2 FC
Spark YG™ 570 anti-mouse CD3 17A2 IHC-F
PE/Fire™ 700 anti-mouse CD3 17A2 FC
PE/Cyanine5 anti-mouse CD3 17A2 FC
Spark Blue™ 574 anti-mouse CD3 Antibody 17A2 FC
Spark Violet™ 423 anti-mouse CD3 17A2 FC
PE/Fire™ 810 anti-mouse CD3 17A2 FC
Spark Red™ 718 anti-mouse CD3 17A2 FC
Spark UV™ 387 anti-mouse CD3 17A2 FC
Go To Top Version: 1    Revision Date: 11.30.2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account